Reproductive Toxicity Evaluation of Cardiovascular Drugs

The results of reproductive toxicity evaluation are an important and critical basis for supporting the entry of drugs into clinical studies and marketing. Ace Therapeutics can provide professional and comprehensive reproductive toxicity evaluation services to advance preclinical research for cardiovascular drugs.

Overview of Reproductive Toxicity of Cardiovascular Drugs

In the clinical field of cardiovascular drug therapy, many cardiovascular drugs often require long-term use, in which case their effects on the human reproductive system need to be fully considered. Reproductive toxicity studies of cardiovascular drugs focus on evaluating the damage to the reproductive system and the adverse effects on the offspring. Reproductive toxicity of cardiovascular drugs may be manifested during pregnancy, or may occur during preconception or lactation, with specific effects on the formation of germ cells, fertilization of the oocyte, and formation and development of the embryo, delivery and breastfeeding.

Fig. 1 Adverse effect of NPs in the reproductive cell organs and molecules. (Wang R, et al., 2018)

Ace Therapeutics can provide preclinical reproductive toxicity evaluation for cardiovascular drugs, often using rats and rabbits as the experimental animal models. When developing a comprehensive reproductive toxicity testing strategy, we can use the following three-phase in vivo procedure to assess reproductive toxicity.

Ace Therapeutics is committed to providing specialized outsourcing services for cardiovascular drug development. We can provide preclinical reproductive toxicity studies for cardiovascular drugs according to our clients' needs. If you are interested in our services, please don't hesitate to contact us.

1. Wang, R.; et al. Potential adverse effects of nanoparticles on the reproductive system. Int J Nanomedicine. 2018, 13:8487-8506.